Trevi Therapeutics announced that CANAL, its proof-of-concept Phase 2 trial evaluating Haduvio (nalbuphine extended-release tablets) for the treatment of chronic cough in people with idiopathic pulmonary fibrosis (IPF) has finished enrolling. The trial (NCT04030026), which is taking place in the U.K., has enrolled about 40 IPF patients…
Patient registries are a hot topic of rare disease research and many organizations are taking advantage of this resource by signing up their patient communities and connecting with researchers. Eric Sid, MD, program officer for the Office of Rare Diseases Research (ORDR), said it is difficult to estimate how…
Problems in the metabolism of low-density lipoprotein (LDL) — also known as “bad cholesterol” — and its receptor contribute to changes in lung cells that ultimately lead to pulmonary fibrosis (PF), an analysis of fibrotic lung tissue and cell and animal models suggests. Notably, a combination of two approved…
It’s normal for people to come and go in our life. Our circle of friends changes when we change schools, start a new job, get married or divorced, and have children. Being diagnosed with idiopathic pulmonary fibrosis (IPF) had the same effect on my group of friends. As my IPF…
Eperisone — an oral muscle relaxant used to treat muscle spasms and rigidity — significantly eased lung scarring and improved lung function in a mouse model of idiopathic pulmonary fibrosis (IPF), a study shows. Comparisons between eperisone and the approved IPF therapies Ofev (nintedanib) and Esbriet (pirfenidone) in…
OncoArendi Therapeutics and the University of Michigan (U-M) have signed an option-to-license agreement, allowing the Poland-based biotech company to develop new therapies to treat fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). “We are thrilled to be partnering with the University of Michigan, one of the world’s leading research…
Have you ever gotten into the car, started driving, and then snapped out of a trance at your destination with no memory of the trip? Let’s call it driving on autopilot. Relying on your reflexes to operate a vehicle is certainly one way to get from point A…
RXC007, an experimental oral treatment of idiopathic pulmonary fibrosis (IPF) being developed by Redx Pharma, continues to be safe and well-tolerated in a Phase 1 study in healthy volunteers, the company reported. “Clinical data from our Phase 1 study suggests that RXC007 is safe and well-tolerated at the drug doses…
No one will ever convince me that COVID-19 is just a cold. Unfortunately, I’ve heard this sentiment echoed by healthy friends since the start of the pandemic as a means of downplaying public health measures meant to curb the spread of the virus. But having had COVID-19 twice now, I’ll…
Bridge Biotherapeutics has entered into an exclusive option-to-license agreement with Cellion BioMed to develop BBT-301, an experimental ion modulator therapy, as a potential treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases. “We are highly excited to in-license BBT-301, a novel drug candidate for the treatment of fibrotic…
Get regular updates to your inbox.
